Taiwan Fusion Biopsy Market Size & Outlook, 2026-2034
Taiwan Fusion Biopsy Market Insights
- According to Reed Intelligence analysis, the Taiwan Fusion Biopsy Market size was USD 18.31 Million in 2025 and is projected to reach USD 41.51 Million by 2034.
- The Taiwan market is projected to grow at a CAGR of 9.6% between 2026 and 2034.
- By segment, MRI-Ultrasound Fusion Biopsy emerged as the largest By Type in terms of market size in 2025.
- Cognitive Fusion Biopsy is anticipated to remain the most attractive By Type segment, recording the fastest growth during the forecast period.
![Taiwan Fusion Biopsy Market Size, Share & Growth Analysis By [2034]](https://reedintelligence.com/uploads/charts/taiwan-fusion-biopsy-market-taiwan-by-type-145314.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Taiwan accounted for 1.01% of the global Fusion Biopsy Market size in 2025.
- By 2034, United States is expected to remain the top global market in terms of size.
- Within Asia Pacific, China is forecasted to dominate the regional Fusion Biopsy Market size by 2034.
- Singapore will be the fastest-growing market in Asia Pacific, projected to achieve USD 14.39 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 18.31 Million |
| Market Size In 2034 | USD 41.51 Million |
| Largest segment | MRI-Ultrasound Fusion Biopsy |
| Units | Revenue in USD Million |
| CAGR | 9.6% (2026-2034) |
| Segmnetation Covered | |
| By Type |
|
| By Application |
|
| By End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Taiwan Fusion Biopsy Market By Type 2026-2034 (USD Million)
| By Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRI-Ultrasound Fusion Biopsy | XX.x | XX.x | XX.x | 9.16 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cognitive Fusion Biopsy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Transperineal Fusion Biopsy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Taiwan Fusion Biopsy Market By Application 2026-2034 (USD Million)
| By Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prostate Cancer Diagnosis | XX.x | XX.x | XX.x | 8.94 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Focal Therapy Planning | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Active Surveillance Monitoring | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Taiwan Fusion Biopsy Market By End Use 2026-2034 (USD Million)
| By End Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 8.72 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostic Imaging Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
